Bio Solution Co.,Ltd. Logo

Bio Solution Co.,Ltd.

Develops cell therapies for degenerative diseases and supplies bio-lab reagents for R&D.

086820 | KO

Overview

Corporate Details

ISIN(s):
KR7086820008
LEI:
Country:
South Korea
Address:
서울특별시 노원구 공릉로 232 5층 (공릉동, 서울테크노파크), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Based on the provided sources, Bio Solution Co., Ltd. is a biotechnology and life sciences company, not a financial data provider. The company develops, manufactures, and sells cell therapy products for degenerative diseases. Its offerings include CartiLife, an autologous chondrocyte cell-based therapy. Additionally, the company produces and supplies a range of bio-laboratory reagents and kits for research and development purposes. These products are used in applications such as yeast two-hybrid assays, nucleic acid precipitation, and protein and DNA electrophoresis. The company is ISO 13485:2016 certified, indicating adherence to quality management standards for medical devices.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-17 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청) (펠렛형 동종 연골세포치료제(카티로이드)의 호주 제1/2상 임상시험계획 승…
Korean 8.9 KB
2025-08-25 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-07-01 00:00
Related Party Transaction
금전대여결정
Korean 19.4 KB
2025-06-05 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-06-05 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (펠렛형 동종 연골세포치료제(카티로이드)의 제1/2상 임상시험계획 승인신청 반려)
Korean 8.8 KB
2025-05-30 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-05-29 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 27.7 KB
2025-05-26 00:00
Share Issue/Capital Change
권리락 (무상증자)
Korean 3.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 880.1 KB
2025-05-13 00:00
Share Issue/Capital Change
주권매매거래정지 (무상증자)
Korean 4.8 KB
2025-05-13 00:00
Share Issue/Capital Change
주요사항보고서(무상증자결정)
Korean 12.0 KB
2025-05-13 00:00
Share Issue/Capital Change
주주명부폐쇄기간또는기준일설정
Korean 4.4 KB
2025-05-09 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-05-09 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB

Automate Your Workflow. Get a real-time feed of all Bio Solution Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Bio Solution Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Bio Solution Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Chemomab Therapeutics Ltd. Logo
Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.
United States of America
CMMB
CHINA PHARMA HOLDINGS, INC. Logo
Develops, manufactures, and sells prescription, OTC, and nutritional products for human use.
United States of America
CPHI
China SXT Pharmaceuticals, Inc. Logo
Researches, produces, and sells advanced Traditional Chinese Medicine (TCM) herbal products.
United States of America
SXTC
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea
034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan
4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden
CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America
CING
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway
CRNA
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America
CTOR
Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America
CTXR

Talk to a Data Expert

Have a question? We'll get back to you promptly.